Fmr LLC Pyxis Oncology, Inc. Transaction History

Fmr LLC

$1.6 Trillion
Q4 2024

A detailed history of Fmr LLC transactions in Pyxis Oncology, Inc. stock. As of the latest transaction made, Fmr LLC holds 84,888 shares of PYXS stock, worth $78,096. This represents 0.0% of its overall portfolio holdings.

Number of Shares

84,888

Previous 3,972 2037.16%

Holding current value

$78,096

Previous $14,000 835.71%

% of portfolio

0.0%

Previous 0.0%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$1.54 - $4.77 $124,610 - $385,969	80,916 Added 2037.16%	84,888 $131,000
Q3 2024 Nov 13, 2024	BUY	$2.83 - $3.94 $11,240 - $15,649	3,972 New	3,972 $14,000
Q1 2024 May 13, 2024	BUY	$2.03 - $6.59 $2 - $6	1 New	1 $0
Q3 2023 Nov 13, 2023	BUY	$1.6 - $2.78 $280 - $486	175 Added 102.34%	346 $0
Q2 2023 Aug 11, 2023	BUY	$2.46 - $4.07 $420 - $695	171 New	171 $0
Q3 2022 Nov 10, 2022	SELL	$1.88 - $3.03 $5 - $9	-3 Reduced 0.35%	855 $2,000
Q2 2022 Aug 12, 2022	BUY	$2.02 - $4.53 $1,472 - $3,302	729 Added 565.12%	858 $2,000
Q1 2022 May 13, 2022	BUY	$4.04 - $11.43 $521 - $1,474	129 New	129 $1,000

Others Institutions Holding PYXS

# of Institutions

100

Shares Held

24.3M

Call Options Held

993K

Put Options Held

42.6K

View Full List

About Pyxis Oncology, Inc.

Ticker PYXS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,096,400
Market Cap $32.3M
Description
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...

More about PYXS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account